• KimDo JunDJhttps://orcid.org/0000-0001-6861-5261Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea., Woo Jin Kim, Myoungnam Lim, Yoonki Hong, Seung-Joon Lee, Seok-Ho Hong, Jeongwon Heo, Hui-Young Lee, and Seon-Sook Han.
• Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.
• J. Korean Med. Sci. 2018 Jun 25; 33 (26): e178.

BackgroundLung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).MethodsBlood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.ResultsThe mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL, P < 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (P = 0.014).ConclusionPlasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.

19 keywords...

hide…